Target intelligence / Profile preview

Rab interacting factor (RABIF)

Target
RABIF
Molecular classification
Chaperone (Rab-stabilizing holdase chaperone), Other (previously proposed as a guanine nucleotide exchange factor for Rab GTPases, but now understood to function primarily as a chaperone)
01

Overview

Rab interacting factor (RABIF) is a highly conserved, soluble protein that acts as a crucial chaperone for Rab GTPases, maintaining their stability and preventing their degradation. While originally described as a guanine nucleotide exchange factor (GEF), more recent studies have demonstrated that RABIF functions predominantly as a holdase chaperone, ensuring proper folding and cellular levels of multiple Rab proteins involved in vesicular trafficking, such as Rab10, Rab8, and Rab13. This function is vital for processes like insulin-stimulated GLUT4 exocytosis in adipocytes, where RABIF deficiency results in defective exocytosis and glucose uptake. Beyond its role in vesicle transport, RABIF expression is dynamically regulated by cellular stress and contributes to cell survival by modulating the JNK MAPK pathway and inhibiting apoptosis. Aberrant overexpression of RABIF has been linked to tumor progression in hepatocellular carcinoma, in part via regulation of mitophagy and glucose metabolism pathways, identifying it as a potential therapeutic target.

Other names
MSS4RASGRF3RASGFR3mss4mammalian suppressor of SEC4Rab-interacting factorguanine nucleotide exchange factor MSS4Ras-specific guanine-releasing factor 3
02

Mechanism of action

Chaperone-mediated stabilization of Rab GTPases (e.g., Rab10, Rab8, Rab13). Anti-apoptotic effect via interaction with stress response/apoptosis signaling pathways. Putative role in therapeutic sensitization to kinase inhibitors (e.g., sorafenib).

03

Biological functions

Regulation of Rab GTPase stabilityVesicular transport (exocytosis and endocytosis)Regulation of insulin-stimulated GLUT4 exocytosisCellular stress responseInhibition of apoptosis
04

Disease associations

Cancer (notably hepatocellular carcinoma progression and tumor growth)Other (potential impact in glucose metabolism via effects on GLUT4)
05

Safety considerations

Potential off-target effects relating to disruption of vesicular transport and Rab stabilityImpaired insulin-stimulated glucose transport and increased apoptosis risk with RABIF inhibition
06

Interacting drugs

Sorafenib
07

Biomarkers

Elevated RABIF expression as a marker for hepatocellular carcinoma progression

Beyond the preview

Go deeper on Rab interacting factor (RABIF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rab interacting factor (RABIF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call